Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30219628

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Oct
First author
Dummer R

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Oct;19(10):1263-1264. doi: 10.1016/S1470-2045(18)30530-8.
    note
    Source null
    related pmid
    30219625
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Oct;19(10):e509. doi: 10.1016/S1470-2045(18)30705-8.
    note
    Source null
    related pmid
    30303122
    relationship
    Erratum in

Authors and identifiers

  1. name
    Dummer R
    type
    Author
  2. name
    Ascierto PA
    type
    Author
  3. name
    Gogas HJ
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Mandala M
    type
    Author
  6. name
    Liszkay G
    type
    Author
  7. name
    Garbe C
    type
    Author
  8. name
    Schadendorf D
    type
    Author
  9. name
    Krajsova I
    type
    Author
  10. name
    Gutzmer R
    type
    Author
  11. name
    Chiarion Sileni V
    type
    Author
  12. name
    Dutriaux C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dummer R
    type
    Author
  2. name
    Ascierto PA
    type
    Author
  3. name
    Gogas HJ
    type
    Author
  4. name
    Arance A
    type
    Author
  5. name
    Mandala M
    type
    Author
  6. name
    Liszkay G
    type
    Author
  7. name
    Garbe C
    type
    Author
  8. name
    Schadendorf D
    type
    Author
  9. name
    Krajsova I
    type
    Author
  10. name
    Gutzmer R
    type
    Author
  11. name
    Chiarion Sileni V
    type
    Author
  12. name
    Dutriaux C
    type
    Author
bibliography ids
  1. nci-bib-9d0ff34f3952df14f256099f
book metadata
content sha256
4f4c17c45469153600342aeb293cc027572f362764fdca5af530ae1ff666121e
document type
citation
dois
  1. 10.1016/S1470-2045(18)30497-2
electronic publication date
display
2018 Sep 12
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30219628
immutable id
pubmed:30219628@4f4c17c45469153600342aeb293cc027572f362764fdca5af530ae1ff666121e
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1315-1327
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Oct;19(10):1263-1264. doi: 10.1016/S1470-2045(18)30530-8.
    note
    Source null
    related pmid
    30219625
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Oct;19(10):e509. doi: 10.1016/S1470-2045(18)30705-8.
    note
    Source null
    related pmid
    30303122
    relationship
    Erratum in
outcomes validated
false
pmid
30219628
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
cc04d75ec3970d67840b48acd2dc3a1ac685d926feb826b76fb920c7d8ed07df
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Oct
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30219628/
title
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice